A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Paliperidone Palmitate in Patients With Schizophrenia
Phase 1
Completed
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2012-03-21
- Last Posted Date
- 2017-09-18
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 328
- Registration Number
- NCT01559272
A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia
Phase 3
Completed
- Conditions
- Schizophrenia
- Interventions
- Drug: Placebo (20% Intralipid emulsion)Drug: PP3M 175 mg eq.Drug: PP3M 263 mg eq.Drug: PP3M 350 mg eq.Drug: PP3M 525 mg eq.
- First Posted Date
- 2012-02-09
- Last Posted Date
- 2016-05-11
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 509
- Registration Number
- NCT01529515
A Study to Evaluate the Effectiveness and Safety of Paliperidone Palmitate in Subjects With Acute Schizophrenia
- First Posted Date
- 2012-02-07
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 212
- Registration Number
- NCT01527305
Safety, Tolerability and Pharmacodynamic Activity of JNJ-26528398 in Healthy Male Participants
- First Posted Date
- 2012-01-27
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 19
- Registration Number
- NCT01520142
A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate
Phase 3
Completed
- Conditions
- Metastatic Breast CancerMetastatic Castration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2012-01-25
- Last Posted Date
- 2022-05-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 32
- Registration Number
- NCT01517802
A Pharmacokinetic Study of Abiraterone Acetate in Patients With Severe Hepatic Impairment Compared to Patients With Normal Hepatic Function
Phase 1
Completed
- Conditions
- Hepatic Impairment
- Interventions
- Drug: Cohort 1Drug: Cohort 2
- First Posted Date
- 2012-01-24
- Last Posted Date
- 2014-06-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 16
- Registration Number
- NCT01516047
A Study of Tapentadol Immediate-Release in the Treatment of Patients With Acute Pain From Bunionectomy
Phase 3
Completed
- Conditions
- Hallux Valgus
- Interventions
- First Posted Date
- 2012-01-24
- Last Posted Date
- 2014-04-28
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 353
- Registration Number
- NCT01516008
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
Phase 3
Completed
- Conditions
- Schizophrenia
- Interventions
- Drug: PP3M 175 mg eq.Drug: PP1M 50 mg eq.Drug: PP3M 263 mg eq.Drug: PP1M 75 mg eq.Drug: PP1M 100 mg eq.Drug: PP3M 350 mg eq.Drug: PP3M 525 mg eq.Drug: PP1M 150 mg eq.Drug: Placebo (20% Intralipid)
- First Posted Date
- 2012-01-24
- Last Posted Date
- 2016-05-02
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1429
- Registration Number
- NCT01515423
A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome
Phase 2
Terminated
- Conditions
- Myelodysplastic Syndrome
- Interventions
- First Posted Date
- 2012-01-20
- Last Posted Date
- 2014-09-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 76
- Registration Number
- NCT01513317
A Study of Canagliflozin and Metformin Immediate Release (50 mg/500 mg) FDC Tablets in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2012-01-11
- Last Posted Date
- 2013-01-31
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 64
- Registration Number
- NCT01508195
© Copyright 2025. All Rights Reserved by MedPath